| Company Name: |
Accela ChemBio Inc. |
| Tel: |
+1-858-6993322 |
| Email: |
info@accelachem.com |
| Products Intro: |
Product Name:Sodium (R)-3-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-Ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl Sulfate
CAS:1000403-03-1
Purity:>95% Package:0.25g Remarks:SY416548
|
|
|
|
|
INT-767 manufacturers
- INT-767
-
- $399.00 / 1mg
-
2024-11-20
- CAS:1000403-03-1
- Min. Order:
- Purity: 98%
- Supply Ability: 10g
- INT-767
-
- $399.00 / 1mg
-
2024-11-19
- CAS:1000403-03-1
- Min. Order:
- Purity: 98%
- Supply Ability: 10g
|
| | INT-767 Basic information |
| Product Name: | INT-767 | | Synonyms: | INT-767;INT-767
(INT767);Sodium (R)-3-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-Ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl Sulfate | | CAS: | 1000403-03-1 | | MF: | C25H45NaO6S | | MW: | 496.68 | | EINECS: | | | Product Categories: | | | Mol File: | 1000403-03-1.mol |  |
| | INT-767 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : ≥ 205.5 mg/mL (415.44 mM) | | form | Solid | | color | White to off-white |
| | INT-767 Usage And Synthesis |
| Description | INT-767 is a G-protein coupled/Farnesoid X-activated receptor agonist potentially for the treatment of hepatic fibrosis. INT-767 significantly improved serum liver enzymes, hepatic inflammation, and biliary fibrosis in Mdr2(-/-) mice. INT-767 significantly induced bile flow and biliary HCO?3- output, as well as gene expression of carbonic anhydrase 14, an important enzyme able to enhance HCO?3- transport, in an Fxr-dependent manner. In addition, INT-767 dramatically reduced bile acid synthesis via the induction of ileal Fgf15 and hepatic Shp gene expression, thus resulting in significantly reduced biliary bile acid output in Mdr2(-/-) mice. | | Uses | INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC50s of 30 and 630 nM, respectively[1][2]. | | in vivo | INT-767 (10-20 mg/kg; i.p.; daily for 2 weeks) decreases plasma total cholesterol and triglyceride levels in db/m and db/db mice [2]. | Animal Model: | Male 8-week old C57BKS/J db/db mice, control nondiabetic db/m mice[2] | | Dosage: | 10, 20 mg/kg | | Administration: | Intraperitoneal injection; daily for 2 weeks | | Result: | Decreased plasma total cholesterol and triglyceride levels. |
| | References | [1] Baghdasaryan A, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mousecholangiopathy model by promoting biliary HCO3- output. Hepatology. 2011 Oct;54(4):1303-1312. DOI:10.1002/hep.24537
[2] Rizzo G, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor andTGR5 agonist. Mol Pharmacol. 2010 Oct;78(4):617-630. DOI:10.1124/mol.110.064501 |
| | INT-767 Preparation Products And Raw materials |
|